Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175]

Study limitation reported by the research below: “Age group tagged as 'adult' — the paper does not specify exact age breakdown; no pediatric patients are implied in this NSCLC surgical trial context.”